Verekitug has shown promise in preclinical studies for the treatment of severe asthma. Credit: catinsyrup/ Shutterstock.com.

Upstream Bio has announced the commencement of patient dosing in its Phase II VALIANT clinical trial of verekitug (UPB-101) for severe asthma.

The recombinant fully human immunoglobulin G1 monoclonal antibody blocks the thymic stromal lymphopoietin receptor (TLSPR) to inhibit TSLP-driven inflammation.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The randomised, double-blind, placebo-controlled VALIANT trial is designed to assess the efficacy of verekitug in severe asthma through a 24-week dosing regimen, aiming to establish its potential as a best-in-class treatment.

Patients will receive either 100mg and 400mg of verekitug every 24 weeks, 100mg every 12 weeks, or a placebo.

The primary endpoint is the annual asthma exacerbation rate (AAER).

See Also:

In a Phase II trial, verekitug is being studied for patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Upstream Bio CEO Sam Truex said: “Verekitug has the potential to be a best-in-class inhibitor of TSLP signaling based on its swift, substantial and sustained effect on clinically relevant biomarkers that are known to correlate with impact on AAER.

“Our team is thrilled to carry our momentum from Phase Ib into our global Phase II studies where we intend to demonstrate how verekitug’s high potency translates to clinical outcomes that will benefit patients with many types of asthma.”

Verekitug has shown promise in preclinical studies.

Its safety and tolerability have been confirmed in three Phase I studies. A Phase Ib study revealed that the antibody maintained maximal inhibition of disease-related biomarkers in asthma patients for 24 weeks post-dose.

Upstream Bio chief medical officer and R&D head Aaron Deykin said: “We are thrilled to initiate the Phase II study in severe asthma after the findings from our multiple ascending dose (MAD) study in asthma patients demonstrated that verekitug produces a compelling reduction in disease-related biomarkers.”